CG Invites

We strive to be a global biopharma leader whose mission is

to develop innovative, life-changing medicine

Core Platform Technologies

Core Platform Technologies Application
Soluble Protein Solution
(Soluble Protein Solution)
Technology to solve the three-dimensional structure of disease-causing protein targets. Structure-based drug discovery begins with identifying the structure of relevant disease-causing proteins. Water-soluble protein must be obtained in high concentration in order to make the protein crystal. However, since most protein targets in humans are insoluble in external systems (e.g., in vitro prokaryote and mammalian cell lines), the biggest obstacle to conducting structural proteomics is obtaining high concentrations of water-soluble proteins. However, using our SPS™ technology, we are able to obtain high-concentrations of water-soluble, pure proteins. Then, we can solve the high-resolution, three-dimensional structure of drug target proteins through NMR* and X-ray diffraction.
*NMR: Nuclear Magnetic Resonance.
Structural ChemoProteomics
(Structural Chemo Proteomics)
Technology for lead discovery using three-dimensional structural information of disease-causing protein targets. Our SCP™ platform consists of three different technologies:
SCPIn Silico Screening can select novel scaffold and lead compounds, which bind to active sites of target proteins from a virtual chemical library. The SCP ™ Library is a collection of these unique compounds made using CG Invites' proprietary technology and expertise.
SCP ™ NMR is then used to determine the location and properties of the binding between the lead compound and target protein.
Structural-based Drug Factory
(SStructural-Based Drug Factory)
Technology for optimizing leads into drug candidates SDF ™ X-ray technology can use the three-dimensional complex structure of the lead compound and the target protein for generating the new drug candidate. When developing a new drug candidate by optimizing the compound based on its three-dimensional structure, the technology can be used to selectively design the drug candidate, modifying our candidate to avoid potential side effects observed in similar drugs. In addition, after optimizing leading substances through SDF ™ Lead informatics, we can synthesize the final drug candidate for development and verify the mechanism of action in various in vitro and in vivo studies.